A double-blind, placebo controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.

Trial Profile

A double-blind, placebo controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs ATL 1102 (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Antisense Therapeutics
  • Most Recent Events

    • 28 Oct 2017 Results of post-hoc analysis measuring effect of ATL1102 on the conversion of remaining new active lesions to T1 black holes, presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 09 Sep 2015 Results published in Antisense Therapeutics media release.
    • 22 Sep 2014 Trial results published in the medical journal Neurology, as reported in an Antisense Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top